Direct radiolabeling of antibody against stage specific embryonic antigen for diagnostic imaging
Abstract
Antibodies against stage specific embryonic antigen-1 is radiolabeled by direct means with a radionuclide for use in detection of occult abscess and inflammation. Radiolabeling is accomplished by partial reduction of the disulfide bonds of the antibody using Sn(II), or using other reducing agents followed by the addition of Sn(II), removal of excess reducing agent and reduction by-products, and addition of a specified amount of radionuclide reducing agent, such as stannous tartrate. The resulting product may be stored frozen or lyophilized, with radiolabeling accomplished by the addition of the radionuclide. No Drawings
- Inventors:
- Issue Date:
- OSTI Identifier:
- 6925998
- Patent Number(s):
- 5346687
- Application Number:
- PPN: US 7-816476
- Assignee:
- Rhomed Inc., Albuquerque, NM (United States)
- DOE Contract Number:
- FG04-89ER60899
- Resource Type:
- Patent
- Resource Relation:
- Patent File Date: 3 Jan 1992
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 62 RADIOLOGY AND NUCLEAR MEDICINE; ANTIBODIES; LABELLING; ANTIGEN-ANTIBODY REACTIONS; DIAGNOSTIC USES; IMAGE PROCESSING; PROCESSING; USES; 550601* - Medicine- Unsealed Radionuclides in Diagnostics
Citation Formats
Rhodes, B A. Direct radiolabeling of antibody against stage specific embryonic antigen for diagnostic imaging. United States: N. p., 1994.
Web.
Rhodes, B A. Direct radiolabeling of antibody against stage specific embryonic antigen for diagnostic imaging. United States.
Rhodes, B A. Tue .
"Direct radiolabeling of antibody against stage specific embryonic antigen for diagnostic imaging". United States.
@article{osti_6925998,
title = {Direct radiolabeling of antibody against stage specific embryonic antigen for diagnostic imaging},
author = {Rhodes, B A},
abstractNote = {Antibodies against stage specific embryonic antigen-1 is radiolabeled by direct means with a radionuclide for use in detection of occult abscess and inflammation. Radiolabeling is accomplished by partial reduction of the disulfide bonds of the antibody using Sn(II), or using other reducing agents followed by the addition of Sn(II), removal of excess reducing agent and reduction by-products, and addition of a specified amount of radionuclide reducing agent, such as stannous tartrate. The resulting product may be stored frozen or lyophilized, with radiolabeling accomplished by the addition of the radionuclide. No Drawings},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {Tue Sep 13 00:00:00 EDT 1994},
month = {Tue Sep 13 00:00:00 EDT 1994}
}
Search for the full text at the U.S. Patent and Trademark Office
Note: You will be redirected to the USPTO site, which may require a pop-up blocker to be deactivated to view the patent. If so, you will need to manually turn off your browser's pop-up blocker, typically found within the browser settings. (See DOE Patents FAQs for more information.)
Save to My Library
You must Sign In or Create an Account in order to save documents to your library.